SCHEMBL5189031

SCHEMBL5189031

CCCOc1ccccc1NC(=O)CC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.65
RAB9A P51151 1/20 0.65
GAA P10253 2/20 0.62
ALDH1A1 P00352 3/20 0.62
MAPT P10636 3/20 0.62
LMNA P02545 2/20 0.62
PKM P14618 1/20 0.62
HTT P42858 1/20 0.62
NLRP1 Q9C000 1/20 0.62
ALOX15 P16050 1/20 0.57
HSD17B10 Q99714 1/20 0.57
CYP2C19 P33261 1/20 0.56
KMT2A Q03164 3/20 0.56
TSHR P16473 4/20 0.52
POLB P06746 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MRGPRX1 Q96LB2 1/20 0.52
NPSR1 Q6W5P4 1/20 0.51
ATM Q13315 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13652613 0.89 GAA (0.60) NPC1RAB9AGAAALDH1A1MAPT
SCHEMBL5188518 0.87 GAA (0.81) NPC1GAAALDH1A1LMNACYP2C19
SCHEMBL18415529 0.87 NPC1 (0.68) NPC1RAB9AGAAALDH1A1MAPT
SCHEMBL7959649 0.85 RAB9A (0.67) NPC1RAB9AGAAALDH1A1MAPT
SCHEMBL10748359 0.85 MAPT (0.72) NPC1RAB9AGAAALDH1A1MAPT
SCHEMBL13652639 0.85 GAA (0.56) NPC1RAB9AGAAHTTHSD17B10
SCHEMBL7465996 0.84 GAA (0.62) GAAALDH1A1HTTCYP2C19KMT2A
SCHEMBL7959643 0.84 NPC1 (0.65) NPC1RAB9AGAAALDH1A1MAPT
SCHEMBL10457597 0.84 NPC1 (0.65) NPC1RAB9AGAAALDH1A1MAPT
SCHEMBL7354067 0.84 GAA (0.55) NPC1RAB9AGAAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP disclosed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO disclosed